Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kellie Vaught

Nurse Practitioner Beckley, WV Nurse Practitioner

NPI 1659326742 CMS profile 10908098

3155 Robert C Byrd Dr, Beckley, WV 25801

Open in the dashboard

General payments

$17,336

879 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kellie Vaught of Beckley, WV is reported in the CMS Open Payments database as having received $17,336 across 879 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,539 195
2024 General $3,837 201
2023 General $4,506 178
2022 General $2,806 155
2021 General $2,649 150

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kellie Vaught
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kellie Vaught were reported at $3,539. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kellie Vaught Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,649 $135 $40–$426 $132
2022 $2,806 $152 $48–$470 $149
2023 $4,506 $166 $54–$529 $160
2024 $3,837 $173 $55–$556 $164
2025 $3,539 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,216 177 payments
  2. Novartis Pharmaceuticals Corporation $1,585 52 payments
  3. Alexion Pharmaceuticals, Inc. $1,299 46 payments
  4. Pfizer Inc. $1,209 92 payments
  5. UCB, Inc. $903 51 payments
  6. Teva Pharmaceuticals USA, Inc. $738 37 payments
  7. EMD Serono, Inc. $676 21 payments
  8. Biogen, Inc. $635 37 payments
  9. Janssen Pharmaceuticals, Inc $587 22 payments
  10. Argenx US, Inc. $559 29 payments
  11. Other $5,928 315 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,383 865 payments
  2. Travel and Lodging $490 3 payments
  3. Education $444 10 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $2,034 111 payments
  2. UBRELVY $2,032 125 payments
  3. NURTEC ODT Pain $1,194 91 payments
  4. ZAVZPRET $1,066 83 payments
  5. ULTOMIRIS $743 31 payments
  6. VALTOCO $523 27 payments
  7. KESIMPTA $503 27 payments
  8. NURTEC ODT Primary Care $502 30 payments
  9. Briviact $459 29 payments
  10. Austedo XR $405 19 payments
  11. Other $8,799 482 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

446

Median for Nurse Practitioner: 389

Drug cost

$75,293

Median for Nurse Practitioner: $21,885

Branded share of claims

17.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 12 $59,178
Aimovig Autoinjector Erenumab-Aooe Brand 14 $10,393
Memantine Hcl Generic 32 $978
Levetiracetam Generic 33 $823
Primidone Generic 65 $790
Carbidopa-Levodopa Carbidopa/Levodopa Brand 39 $574
Gabapentin Generic 21 $524
Donepezil Hcl Generic 71 $405
Propranolol Hcl Generic 24 $383
Amitriptyline Hcl Generic 46 $329

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$363 — —
UBRELVY
$330 — —
ULTOMIRIS
$200 — —
NURTEC ODT
$196 — —
ZAVZPRET
$196 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

879 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record